Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fabbri

Showing results (371-380 of 438) with videos related to

Pageof 44
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 29, 2007
Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancerPiera Boschetto, Elena Zeni, Lucia Mazzetti, et al.
Oncogene|December 11, 2019
Correction: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essentialS Semba, F Trapasso, M Fabbri, et al.
European Journal of Internal Medicine|June 1, 2020
Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center studyFrancesco Dentali, Fulvio Pomero, Pierpaolo Di Micco, et al.
The Lancet. Respiratory Medicine|September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialGary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Thorax|February 6, 2002
Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokersD Miotto, M D Hollenberg, N W Bunnett, et al.
Oncogene|January 13, 2006
Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essentialS Semba, F Trapasso, M Fabbri, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2010
A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthmaCarlos A Camargo, Deborah M Gurner, Howard A Smithline, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2000
Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphismsM Whyte, R Hubbard, R Meliconi, et al.
Thorax|June 14, 2006
Association between markers of emphysema and more severe chronic obstructive pulmonary diseaseP Boschetto, S Quintavalle, E Zeni, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 5, 2020
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority StudyJaco Voorham, Simonetta Baldi, Luigi Santoro, et al.
Pageof 44

Showing results (371-380 of 438) with videos related to

Sort By:
Pageof 44
Lung Cancer (Amsterdam, Netherlands)|September 29, 2007
Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancerPiera Boschetto, Elena Zeni, Lucia Mazzetti, et al.
Oncogene|December 11, 2019
Correction: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essentialS Semba, F Trapasso, M Fabbri, et al.
European Journal of Internal Medicine|June 1, 2020
Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center studyFrancesco Dentali, Fulvio Pomero, Pierpaolo Di Micco, et al.
The Lancet. Respiratory Medicine|September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialGary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Thorax|February 6, 2002
Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokersD Miotto, M D Hollenberg, N W Bunnett, et al.
Oncogene|January 13, 2006
Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essentialS Semba, F Trapasso, M Fabbri, et al.
The Journal of Allergy and Clinical Immunology|February 18, 2010
A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthmaCarlos A Camargo, Deborah M Gurner, Howard A Smithline, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2000
Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphismsM Whyte, R Hubbard, R Meliconi, et al.
Thorax|June 14, 2006
Association between markers of emphysema and more severe chronic obstructive pulmonary diseaseP Boschetto, S Quintavalle, E Zeni, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 5, 2020
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority StudyJaco Voorham, Simonetta Baldi, Luigi Santoro, et al.
Pageof 44